ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Gustavsson, Heléne ^a   Tešan, Tajana ^a   Jennbacken, Karin ^a   Kuno, Kouji ^b   Damber, Jan Erik ^a   Welén, Karin ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; ANDROGEN; SHORT HAIRPIN RNA; THROMBOSPONDIN 1; ADAM PROTEIN; ADAMTS1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL; BLOOD VESSEL DIAMETER; CANCER GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PERICYTE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TIME; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ADAM PROTEINS; ANIMALS; BLOOD VESSELS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROSTATIC NEOPLASMS; RNA INTERFERENCE; THROMBOSPONDIN 1; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 77953354683     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-288     Document Type: Article

References (31)

1. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005, 115(6):849-860. 10.1002/ijc.20945, 15729716.
2. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999, 274(33):23349-23357. 10.1074/jbc.274.33.23349, 10438512.
3. Iruela-Arispe ML, Carpizo D, Luque A. ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann N Y Acad Sci 2003, 995:183-190. 10.1111/j.1749-6632.2003.tb03221.x, 12814950.
4. Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K. The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun 2004, 319(4):1327-1333. 10.1016/j.bbrc.2004.05.105, 15194513.
5. Liu YJ, Xu Y, Yu Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 2006, 25:2452-2467. 10.1038/sj.onc.1209287, 2759703, 16314835.
6. Rocks N, Paulissen G, Quesada-Calvo F, Munaut C, Gonzalez ML, Gueders M, Hacha J, Gilles C, Foidart JM, Noel A, Cataldo DD. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. Cancer Res 2008, 68(22):9541-9550. 10.1158/0008-5472.CAN-08-0548, 19010931.
7. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem 1997, 272(1):556-562. 10.1074/jbc.272.1.556, 8995297.
8. Luque A, Carpizo DR, Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003, 278(26):23656-23665. 10.1074/jbc.M212964200, 12716911.
9. Lee NV, Sato M, Annis DS, Loo JA, Wu L, Mosher DF, Iruela-Arispe ML. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. Embo J 2006, 25(22):5270-5283. 10.1038/sj.emboj.7601400, 1636613, 17082774.
10. Vallbo C, Wang W, Damber JE. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU Int 2004, 93(9):1339-1343. 10.1111/j.1464-410x.2004.04818.x, 15180634.
11. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, Toyoda E, Tulachan S, Arii S, Doi R, Imamura M. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 2001, 7(11):3437-3443.
12. Porter S, Scott SD, Sassoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res 2004, 10(7):2429-2440. 10.1158/1078-0432.CCR-0398-3, 15073121.
13. Rocks N, Paulissen G, Quesada Calvo F, Polette M, Gueders M, Munaut C, Foidart JM, Noel A, Birembaut P, Cataldo D. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer 2006, 94(5):724-730. 2361209, 16495931.
14. Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000, 42(1):26-33. 10.1002/(SICI)1097-0045(20000101)42:1<26::AID-PROS4>3.0.CO;2-6, 10579796.
15. Khatami A, Pihl CG, Norrby K, Hugosson J, Damber JE. Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy?. Acta Oncol 2005, 44(4):362-368. 10.1080/02841860510029824, 16120545.
16. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 2007, 27(5B):3651-3660.
17. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143(2):401-409. 1887042, 7688183.
18. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997, 33(1):38-45. 10.1002/(SICI)1097-0045(19970915)33:1<38::AID-PROS7>3.0.CO;2-5, 9294625.
19. Gustavsson H, Wang W, Jennbacken K, Welen K, Damber JE. ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int 2009, 104(11):1786-1790. 10.1111/j.1464-410X.2009.08676.x, 19522863.
20. Di Lorenzo G, De Placido S, Autorino R, De Laurentiis M, Mignogna C, D'Armiento M, Tortora G, De Rosa G, D'Armiento M, De Sio M, Bianco AR, D'Armiento FP. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis 2005, 8(1):54-59. 10.1038/sj.pcan.4500768, 15655565.
21. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007, 67(1):41-49. 10.1002/pros.20486, 17044086.
22. Gustavsson H, Jennbacken K, Welen K, Damber JE. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer. Prostate 2008, 68(2):161-170. 10.1002/pros.20672, 18076023.
23. Gustavsson H, Welen K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005, 62(4):364-373. 10.1002/pros.20145, 15389782.
24. Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 2006, 66(15):1631-1640. 10.1002/pros.20469, 16927303.
25. Welen K, Jennbacken K, Tesan T, Damber JE. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer Prostatic Dis 2009, 12(1):41-46. 10.1038/pcan.2008.33, 18521102.
26. Russell DL, Doyle KM, Ochsner SA, Sandy JD, Richards JS. Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation. J Biol Chem 2003, 278(43):42330-42339. 10.1074/jbc.M300519200, 12907688.
27. Mucci LA, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, Stampfer MJ, Clinton SK. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009, 27(33):5627-5633. 10.1200/JCO.2008.20.8876, 19858401.
28. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001, 98(22):12485-12490. 10.1073/pnas.171460498, 60080, 11606713.
29. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat 2009, 114(1):85-96. 10.1007/s10549-008-9992-6, 2631620, 18409060.
30. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002, 282(5):C947-970.
31. Ifon ET, Pang AL, Johnson W, Cashman K, Zimmerman S, Muralidhar S, Chan WY, Casey J, Rosenthal LJ. U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. Cancer Cell Int 2005, 5:19. 10.1186/1475-2867-5-19, 1200560, 15972109.